Quick Answer
FibroBiologics, Inc. reported Net Income Loss of -$18.65 million for the year ending 2025.
- FibroBiologics, Inc. showed a decrease of -67.1% in Net Income Loss from 2024 to 2025.
- This data is from FibroBiologics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$2.42 million | Q2 2023: -$2.16 million | Q3 2023: -$2.19 million | Q1 2024: -$8.46 million | Q2 2024: $898.0 thousand | Q3 2024: -$500.0 thousand | Q1 2025: -$4.97 million | Q2 2025: -$4.66 million | Q3 2025: -$5.78 million.
- Over the full 4 years of available data (2022 to 2025), FibroBiologics, Inc.'s Net Income Loss has declined by 264.1%.
- Historical annual values: Fiscal year 2025: -$18.65 million | Fiscal year 2024: -$11.16 million | Fiscal year 2023: -$16.49 million | Fiscal year 2022: -$5.12 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: